Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O76096

UPID:
CYTF_HUMAN

ALTERNATIVE NAMES:
Cystatin-7; Cystatin-like metastasis-associated protein; Leukocystatin

ALTERNATIVE UPACC:
O76096; Q6FH95; Q7Z4J8; Q9UED4

BACKGROUND:
Cystatin-F stands out in the cystatin superfamily for its selective inhibition of papain and cathepsin L, enzymes crucial for proteolytic processes. Known by alternative names such as Cystatin-7, Cystatin-like metastasis-associated protein, and Leukocystatin, it is implicated in the fine-tuning of immune responses, particularly affecting the hematopoietic system.

THERAPEUTIC SIGNIFICANCE:
The exploration of Cystatin-F's function offers a promising avenue for therapeutic intervention. Given its unique role in immune system regulation and protease inhibition, targeting Cystatin-F could lead to innovative treatments for diseases where immune dysregulation is a key factor.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.